Clinical Trial Update: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL [Phase 2]

View source ↗

Summary

This update covers a Phase 2 trial evaluating shortening treatment duration with acalabrutinib in combination with obinutuzumab for chronic lymphocytic leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING